Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 192 publications
Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards.
Journal: Hematology/oncology clinics of North America
Published: September 02, 2026
TIP26-317: A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWI/SNF Alterations.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 16, 2026
Radiographic Versus Pathology-Integrated Response for Assessing Optimal Surgical Timing After Neoadjuvant Imatinib in Patients With Locally Advanced KIT Exon 11-Mutant GIST.
Journal: Annals of surgery
Published: April 06, 2026
TIP26-317: A Single-arm, Open-label, Phase II Trial of Cemiplimab Plus Gemcitabine as Second-Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma Harboring SWI/SNF Alterations.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
PD-L2 Landscape and Correlation with Outcome: An Immunomic Analysis.
Journal: JCO oncology advances
Published: January 22, 2026
Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 08, 2026
Preoperative Avapritinib for Localized PDGFRA-Mutant GIST: Marked Pathologic Response, but Limited Feasibility at Standard Dosing.
Journal: Cancer medicine
Published: January 05, 2026
OX40 transcriptomic expression and its association with immune checkpoints and clinical outcomes.
Journal: Therapeutic advances in medical oncology
Published: December 28, 2025
Anaplastic thyroid cancer: review of precision therapy options and advances.
Journal: NPJ precision oncology
Published: December 22, 2025
Interleukin-2 transcriptomic expression correlates with prolonged survival and with GNAS alterations in patients with advanced cancers.
Journal: ESMO open
Published: December 19, 2025
Context-Dependent Survival Associations Between Interleukin-13 Expression and Immunotherapy in Advanced Solid Tumors.
Journal: ImmunoTargets and therapy
Published: December 05, 2025
Targeting BRAF Class II and III Mutations in NSCLC with the pan-RAF inhibitor Exarafenib Reveals ARAF-KSR1-Mediated Resistance and Rational Combination Strategies.
Journal: Research square
Published: November 24, 2025
Last Updated: 09/26/2026